PT3762380T - Agonistas do recetor do péptido de fenilpirrolidinona formilo 2 - Google Patents

Agonistas do recetor do péptido de fenilpirrolidinona formilo 2

Info

Publication number
PT3762380T
PT3762380T PT197117690T PT19711769T PT3762380T PT 3762380 T PT3762380 T PT 3762380T PT 197117690 T PT197117690 T PT 197117690T PT 19711769 T PT19711769 T PT 19711769T PT 3762380 T PT3762380 T PT 3762380T
Authority
PT
Portugal
Prior art keywords
phenylpyrrolidinone
receptor agonists
formyl peptide
formyl
peptide
Prior art date
Application number
PT197117690T
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3762380T publication Critical patent/PT3762380T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PT197117690T 2018-03-05 2019-03-04 Agonistas do recetor do péptido de fenilpirrolidinona formilo 2 PT3762380T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862638556P 2018-03-05 2018-03-05

Publications (1)

Publication Number Publication Date
PT3762380T true PT3762380T (pt) 2022-01-25

Family

ID=65812419

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197117690T PT3762380T (pt) 2018-03-05 2019-03-04 Agonistas do recetor do péptido de fenilpirrolidinona formilo 2

Country Status (30)

Country Link
US (3) US10676431B2 (pt)
EP (2) EP3981767B1 (pt)
JP (1) JP7155276B2 (pt)
KR (1) KR102803660B1 (pt)
CN (1) CN111868052B (pt)
AR (1) AR114429A1 (pt)
AU (1) AU2019232704B2 (pt)
BR (1) BR112020017744A2 (pt)
CA (1) CA3092927A1 (pt)
CL (1) CL2020002224A1 (pt)
CY (1) CY1124985T1 (pt)
DK (1) DK3762380T3 (pt)
EA (1) EA202092094A1 (pt)
ES (2) ES2904483T3 (pt)
HR (1) HRP20220118T1 (pt)
HU (1) HUE058044T2 (pt)
IL (1) IL277044B2 (pt)
LT (1) LT3762380T (pt)
MX (1) MX2020009000A (pt)
MY (1) MY204384A (pt)
PE (1) PE20210046A1 (pt)
PL (1) PL3762380T3 (pt)
PT (1) PT3762380T (pt)
RS (1) RS62833B1 (pt)
SG (1) SG11202008504SA (pt)
SI (1) SI3762380T1 (pt)
SM (1) SMT202200067T1 (pt)
TW (1) TWI804585B (pt)
WO (1) WO2019173182A1 (pt)
ZA (1) ZA202006115B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538367A (ja) * 2015-11-24 2018-12-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定
CN110996950B (zh) 2017-06-09 2023-04-04 百时美施贵宝公司 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂
ES2869129T3 (es) 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
ES2964299T3 (es) 2018-11-26 2024-04-05 Bristol Myers Squibb Co Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2
ES2946673T3 (es) * 2019-06-18 2023-07-24 Bristol Myers Squibb Co Agonistas del FPR2 de óxido de biaril dialquil fosfina
JP7700210B2 (ja) 2020-07-09 2025-06-30 ブリストル－マイヤーズ スクイブ カンパニー ピラゾロンホルミルペプチド２受容体アゴニスト
KR20230038515A (ko) * 2020-07-09 2023-03-20 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 fpr2 효능제
JP7802765B2 (ja) * 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト
JP7830488B2 (ja) * 2021-01-21 2026-03-16 ベイジン・ティアンタン・ホスピタル Ｆｐｒ１のモジュレーター及びそれを使用する方法
WO2022155860A1 (en) * 2021-01-21 2022-07-28 Biofront Therapeutics (Beijing) Co., Ltd. Modulators of fpr1 and methods of using the same
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
JP2024545270A (ja) 2021-12-15 2024-12-05 アダマ・アガン・リミテッド 種々の農薬及びそのマーカーの調製に有用な化合物
AU2023277074A1 (en) 2022-05-27 2024-12-19 Asahi Group Holdings, Ltd. Fpr2 agonist containing outer membrane vesicles derived from lactic acid bacterium
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
EP4698275A1 (en) * 2023-04-18 2026-02-25 Bristol-Myers Squibb Company Pyrrolidinone urea fpr2 agonists
KR20250175328A (ko) * 2023-04-18 2025-12-16 브리스톨-마이어스 스큅 컴퍼니 피롤리디논 우레아 fpr2 효능제
CN120957970A (zh) * 2023-04-18 2025-11-14 百时美施贵宝公司 碳环苯基吡咯烷酮脲fpr2激动剂
WO2025202955A1 (en) 2024-03-28 2025-10-02 Pi Industries Ltd. Fused bicyclic compounds and their use as pest control agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
HUT75808A (en) 1994-06-02 1997-05-28 Zeneca Ltd Substituted pyrrolidones, thiazolidones and oxazolidones as herbicides and process for their preparation
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TWI354664B (en) * 2003-08-21 2011-12-21 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine rece
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
US7678913B2 (en) * 2004-12-07 2010-03-16 Portola Pharmaceuticals, Inc. Ureas as factor Xa inhibitors
WO2006063293A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. THIOUREAS AS FACTOR Xa INHIBITORS
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
DK2225231T3 (da) 2007-12-18 2011-10-17 Actelion Pharmaceuticals Ltd Aminotriazolderivater som alx-agonister
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5580741B2 (ja) 2008-09-19 2014-08-27 武田薬品工業株式会社 含窒素複素環化合物およびその用途
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
CA2803920A1 (en) 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
KR101847672B1 (ko) 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
CA2816376C (en) 2010-12-07 2018-11-20 Actelion Pharmaceuticals Ltd Oxazolyl-methylether derivatives as alx receptor agonists
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR102001364B1 (ko) 2011-05-13 2019-07-22 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
PT2770989T (pt) 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
WO2013158597A1 (en) 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
AU2014290618B2 (en) 2013-07-16 2018-04-05 Allergan, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
NZ752095A (en) 2013-11-28 2022-07-01 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
MD4889C1 (ro) 2013-12-03 2024-10-31 Фмк Корпорейшн Pirolidinone în calitate de erbicide
MY191956A (en) 2014-05-15 2022-07-20 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
BR112017015760A2 (pt) 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10525058B2 (en) 2015-05-27 2020-01-07 Kyorin Pharmaceutical Co., Ltd Urea derivative or pharmacologically acceptable salt thereof
JP2018538367A (ja) 2015-11-24 2018-12-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定
KR102772801B1 (ko) 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR20190015492A (ko) 2016-06-08 2019-02-13 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학적 화합물
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
ES2869129T3 (es) 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
CN110996950B (zh) 2017-06-09 2023-04-04 百时美施贵宝公司 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
IL277044B2 (en) 2023-10-01
JP7155276B2 (ja) 2022-10-18
EP3762380A1 (en) 2021-01-13
SMT202200067T1 (it) 2022-03-21
KR102803660B1 (ko) 2025-05-02
US11117861B2 (en) 2021-09-14
US20200255375A1 (en) 2020-08-13
PE20210046A1 (es) 2021-01-08
CY1124985T1 (el) 2023-01-05
CN111868052B (zh) 2024-03-08
SG11202008504SA (en) 2020-10-29
TWI804585B (zh) 2023-06-11
DK3762380T3 (da) 2022-01-17
US10676431B2 (en) 2020-06-09
AR114429A1 (es) 2020-09-02
MY204384A (en) 2024-08-27
RS62833B1 (sr) 2022-02-28
ZA202006115B (en) 2022-06-29
KR20200128709A (ko) 2020-11-16
AU2019232704B2 (en) 2024-03-21
AU2019232704A1 (en) 2020-10-22
CN111868052A (zh) 2020-10-30
JP2021516240A (ja) 2021-07-01
IL277044B1 (en) 2023-06-01
US11708327B2 (en) 2023-07-25
PL3762380T3 (pl) 2022-02-21
EP3762380B1 (en) 2021-12-15
SI3762380T1 (sl) 2022-09-30
ES2904483T3 (es) 2022-04-05
ES3061495T3 (en) 2026-04-06
BR112020017744A2 (pt) 2020-12-22
HUE058044T2 (hu) 2022-06-28
HRP20220118T1 (hr) 2022-04-15
EP3981767B1 (en) 2025-12-31
US20190270704A1 (en) 2019-09-05
CL2020002224A1 (es) 2020-11-20
MX2020009000A (es) 2020-10-05
IL277044A (en) 2020-10-29
LT3762380T (lt) 2022-02-25
EA202092094A1 (ru) 2020-12-10
TW202000645A (zh) 2020-01-01
EP3981767A1 (en) 2022-04-13
US20210371378A1 (en) 2021-12-02
CA3092927A1 (en) 2019-09-12
WO2019173182A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
ZA202006115B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
SI3989972T1 (sl) Agonisti receptorja za glukagonu podobni peptid 1
IL279300A (en) 1-GLP agonist receptors and their use
IL279224B1 (en) 1-glp agonist receptors and their use
PT3807267T (pt) Agonistas do recetor da hormona da tiroide e usos dos mesmos
ZA202101537B (en) Anti-trem-2 agonist antibodies
IL259791B (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
ZA202005419B (en) C-terminal antibody variants
EP3549948A4 (en) AGONISTIC PEPTIDE FOR ADIPONECTIN RECEPTOR
GB201810052D0 (en) Polypeptide
GB201817932D0 (en) Peptide synthesis
IL299680A (en) Pyrazolone formyl peptide 2 receptor agonists
GB201817943D0 (en) Galanin-2 receptor agonists
HK40039646A (en) Synthetic rig-i-like receptor agonists
GB201816747D0 (en) Linear apelin receptor agonists
GB201806655D0 (en) Polypeptide